证券代码：600750 证券简称：江中药业 公告编号:2023-025 江中药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）将于 2023 年 8 月 24 日发布公 司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 经营成果和财务状况，公司计划于 2023 年 8 月 29 日下午 15:00-16:30 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年半年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （网址：http://roadshow.sseinfo.com/） 会议召开时间：2023 年 8 月 29 日(星期二)下午 15:00-16:30 会议召开地点：上海证 ...

本次股票发行后拟在创业板市场上市，该市场具有较高的投资风 险。创业板公司具有创新投入大、新旧产业融合成功与否存在不确定性、 尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者 面临较大的市场风险。投资者应充分了解创业板市场的投资风险及本公 司所披露的风险因素，审慎作出投资决定。 创业板 投资风 险提示 杭州民生健康药业股份有限公司 （浙江省杭州市临平区东湖街道新天路 101 号） 首次公开发行股票并在创业板上市 招股意向书 保荐人（主承销商） 1-1-1 杭州民生健康药业股份有限公司 招股意向书 本次发行概况 | 发行股票类型 | 人民币普通股（A股） | | --- | --- | | 发行股数 | 本次拟公开发行新股8,913.86万股，占发行后总股本的比例不 低于25%，本次发行不存在股东公开发售的情形。 | | 每股面值 | 人民币1.00元 | | 每股发行价格 | 【】元 | | 预计发行日期 | 2023年8月22日 | | 拟上市证券交易所和板块 | 深圳证券交易所创业板 | | 发行后总股本 | 35,655.4330万股 | | 保荐人（主承销商） | 财通证券股份有限公司 | ...

本次股票发行后拟在创业板市场上市，该市场具有较高的投资风 险。创业板公司具有创新投入大、新旧产业融合成功与否存在不确定性、 尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者 面临较大的市场风险。投资者应充分了解创业板市场的投资风险及本公 司所披露的风险因素，审慎作出投资决定。 杭州民生健康药业股份有限公司 （浙江省杭州市临平区东湖街道新天路 101 号） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本招股说明书（注 册稿）不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正式公告的招股 说明书全文作为投资决定的依据。 保荐人（主承销商） （浙江省杭州市西湖区天目山路 198 号财通双冠大厦西楼） 创业板 投资风 险提示 杭州民生健康药业股份有限公司 招股说明书（注册稿） 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不 ...

江中药业股份有限公司 关于参加沪市主板生物医药行业上市公司2022年年报 集体业绩说明会暨2023年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）已于2023年3月25日发布了公司 2022年年度报告，于2023年4月27日发布了公司2023年第一季度报告，为便于广大 投资者更全面深入地了解公司2022年度及2023年第一季度经营成果、财务状况，同 时更加充分地向投资者展示生物医药行业发展情况，公司计划于2023年5月12日下 午13:00-14:30参加沪市主板生物医药行业上市公司2022年年报集体业绩说明会，就 投资者关心的问题进行交流。 证券代码：600750 证券简称：江中药业 公告编号：2023-019 具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍 关注问题进行回答 。 二、说明会召开的时间、地点及活动日程 三、参加人员 董事长：刘为权先生 总经理：肖文斌先生 财务总监：李小俊先生 董事会秘书：田永静女 ...

Financial Performance - Operating income for the first nine months was ¥1,883,820,457.72, representing a decrease of 8.26% year-on-year[6] - Net profit attributable to shareholders of the listed company increased by 42.99% to ¥221,963,948.56 for the first nine months[6] - Basic and diluted earnings per share rose by 45.10% to ¥0.74[6] - The weighted average return on equity increased by 2.60 percentage points to 10.28%[6] - Total operating revenue for Q3 2015 was ¥565,591,060.38, a decrease of 14.9% compared to ¥664,627,359.36 in Q3 2014[32] - Net profit for Q3 2015 reached ¥83,231,412.38, an increase of 40.5% from ¥59,164,229.31 in Q3 2014[34] - The company reported a total profit of ¥95,371,295.06 for Q3 2015, up from ¥71,960,829.85 in Q3 2014[34] - The company’s total profit for Q3 2015 was ¥83,204,215.33, a decrease of 24.4% compared to ¥110,053,663.50 in Q3 2014[38] Cash Flow - The net cash flow from operating activities for the first nine months was ¥433,979,515.93, up 54.46% compared to the same period last year[6] - The net cash flow from operating activities for the period was 433.98 million yuan, an increase of 153.01 million yuan, or 54.46%, mainly due to reduced market expenditures leading to lower cash payments related to operating activities.[12] - Cash flow from operating activities for the first nine months of 2015 was ¥433,979,515.93, an increase of 54.4% from ¥280,973,002.56 in the same period last year[42] - Operating cash inflow totaled $1,504,164,634.93, a decrease of 22.5% from $1,944,699,665.57 in the same period last year[45] - Net cash flow from operating activities was $354,212,278.14, down from $372,181,006.07 year-over-year, reflecting a decline of 4.7%[45] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,332,682,024.07, a slight increase of 0.17% compared to the end of the previous year[6] - Current assets totaled ¥1,976,416,459.92, down from ¥2,089,614,193.80 at the beginning of the year, representing a decrease of approximately 5.4%[24] - Non-current assets rose to ¥1,356,265,564.15 from ¥1,237,395,775.13, marking an increase of about 9.6%[25] - Total liabilities amounted to ¥1,065,178,581.00, down from ¥1,193,872,013.57, indicating a decrease of about 10.8%[26] - Current liabilities increased to ¥1,061,652,552.75 from ¥682,977,573.05, representing a significant rise of approximately 55.5%[25] - Shareholders' equity increased to ¥2,267,503,443.07 from ¥2,133,137,955.36, reflecting a growth of approximately 6.3%[26] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,098[8] - The largest shareholder, Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd., held 43.03% of the shares, with 21,200,000 shares pledged[8] Investment Activities - The company plans to invest up to 800 million yuan in a sale-leaseback transaction with Shenzhen Haiji Financing Leasing Co., Ltd., with a financing term of 12 months.[15] - The company acquired 50 million shares of Qinghai Bank, representing 2.69% of its total share capital, for 125.5 million yuan during the reporting period.[16] - The company intends to publicly transfer 51% of its stake in Jiangxi Jiuzhoutong Pharmaceutical Co., Ltd., with the transfer price not less than the assessed value as of September 30, 2015.[17] - The company will use up to 200 million yuan of idle funds for short-term financial investments, with a total entrusted loan balance of 100 million yuan as of October 22, 2015.[18] Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in this report[6] - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[32] Other Financial Metrics - Non-recurring gains and losses totaled ¥7,524,230.91 for the third quarter[7] - Cash and cash equivalents increased to ¥737,220,384.66 from ¥605,526,487.06, reflecting a growth of about 21.7%[24] - Inventory levels slightly decreased to ¥307,897,939.34 from ¥312,827,444.19, a decline of about 1.3%[24] - The company reported a significant reduction in short-term borrowings, decreasing from ¥125,000,000.00 to ¥30,000,000.00, a drop of 76%[25] - Total cash and cash equivalents at the end of Q3 2015 was ¥737,220,384.66, up from ¥661,505,704.06 at the end of Q3 2014[43]